Postpartum Depression: A Clinical Review of Impact and Current Treatment Solutions

• Published in: Drugs (New York, N.Y.) Vol. 84; no. 6; pp. 645 - 659
• Main Authors: Dennis, Cindy-Lee, Singla, Daisy R., Brown, Hilary K., Savel, Katarina, Clark, Crystal T., Grigoriadis, Sophie, Vigod, Simone N.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.06.2024; Springer Nature B.V
• Subjects: Antidepressants; Anxiety; Avoidance behavior; Breast feeding; Breastfeeding & lactation; Children & youth; Comorbidity; Drug development; Drug therapy; Emotional behavior; Epigenetics; Etiology; Families & family life; Genes; Infanticide; Internal Medicine; Medicine; Medicine & Public Health; Mental depression; Neurosteroids; Parents & parenting; Patients; Pharmacology; Pharmacology/Toxicology; Pharmacotherapy; Postpartum; Postpartum depression; Postpartum period; Review Article; Serotonin; Serotonin uptake inhibitors; Sertraline; Womens health; United States > US
• ISSN: 0012-6667; 1179-1950; 1179-1950
• DOI: 10.1007/s40265-024-02038-z

Depression during the first year postpartum (postpartum depression) impacts millions of women and their families worldwide. In this narrative review, we provide a summary of postpartum depression, examining the etiology and consequences, pharmacological and psychological treatments, and potential mechanisms of change and current barriers to care. Psychological treatments are effective and preferred by many perinatal patients over medications, but they often remain inaccessible. Key potential mechanisms underlying their effectiveness include treatment variables (e.g., dosage and therapeutic alliance) and patient behaviors (e.g., activation and avoidance and emotional regulation). Among pharmacological treatments, the selective serotonin reuptake inhibitor (SSRI) sertraline is generally the first-line antidepressant medication recommended to women in the postpartum period due to its minimal passage into breastmilk and the corresponding decades of safety data. Importantly, most antidepressant drugs are considered compatible with breastfeeding. Neurosteroids are emerging as an effective treatment for postpartum depression, although currently this treatment is not widely available. Barriers to widespread access to treatment include those that are systematic (e.g., lack of specialist providers), provider-driven (e.g., lack of flexibility in treatment delivery), and patient-driven (e.g., stigma and lack of time for treatment engagement). We propose virtual care, task-sharing to non-specialist treatment providers, and collaborative care models as potential solutions to enhance the reach and scalability of effective treatments to address the growing burden of postpartum depression worldwide and its negative impact on families and society.